Daptomycin

Journal of Infection

Volumn 55, Issue 3, 2007, Pages 205-213

  Enoch, David A ^a   Bygott, Jeanine M ^a   Daly, Marie Louise ^a   Karas, J Andreas ^a  

^a PAPWORTH HOSPITAL   (United Kingdom)

Author keywords

Bacteraemia and endocarditis; Daptomycin; Gram positive infections; Skin and soft tissue infection

Indexed keywords

AMPICILLIN; AZTREONAM; CEFTRIAXONE; CIPROFLOXACIN; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; FLUCLOXACILLIN; GENTAMICIN; LINEZOLID; METICILLIN; OXACILLIN; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; RIFAMPICIN; SULTAMICILLIN; TETRACYCLINE; TIMENTIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTEREMIA; BACTERIAL ARTHRITIS; BACTERIAL ENDOCARDITIS; BACTERIAL INFECTION; BACTERIAL MEMBRANE; BACTERIAL PNEUMONIA; BACTERIAL STRAIN; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSTIPATION; CREATINE KINASE BLOOD LEVEL; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG PENETRATION; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; EUROPE; GRAM POSITIVE BACTERIUM; HUMAN; KIDNEY DISEASE; LICENCE; LOEFFLER PNEUMONIA; MEMBRANE PERMEABILITY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MULTIDRUG RESISTANCE; NAUSEA; OSTEOMYELITIS; PATHOGENESIS; PERIPHERAL NEUROPATHY; POSTMARKETING SURVEILLANCE; PREVALENCE; RASH; REVIEW; RHABDOMYOLYSIS; SIDE EFFECT; SKIN INFECTION; SOFT TISSUE INFECTION; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS AGALACTIAE; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES; TREATMENT DURATION; TREATMENT OUTCOME; UNITED STATES; URINARY TRACT INFECTION; VOMITING;

ANTI-BACTERIAL AGENTS; BACTEREMIA; DAPTOMYCIN; ENDOCARDITIS; GRAM-POSITIVE BACTERIA; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; STAPHYLOCOCCAL SKIN INFECTIONS;

EID: 34547854766     PISSN: 01634453     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jinf.2007.05.180     Document Type: Review

References (86)

1. Cosgrove S.E., Qi Y., Kaye K.S., Harbarth S., Karchmer A.W., and Carmeli Y. The impact of methicillin resistance in Staphylococcus aureus bacteremia on patient outcomes: mortality, length of stay, and hospital charges. Infect Control Hosp Epidemiol 26 2 (2005) 166-174
2. Cosgrove S.E., Sakoulas G., Perencevich E.N., Schwaber M.J., Karchmer A.W., and Carmeli Y. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin Infect Dis 36 1 (2003) 53-59
3. Wang G., Hindler J.F., Ward K.W., and Bruckner D.A. Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period. J Clin Microbiol 44 11 (2006) 3883-3886
4. Wootton M., Walsh T.R., and MacGowan A.P. Evidence for reduction in breakpoints used to determine vancomycin susceptibility in Staphylococcus aureus. Antimicrob Agents Chemother 49 9 (2005) 3982-3983
5. Reacher M.H., Shah A., Livermore D.M., Wale M.C., Graham C., Johnson A.P., et al. Bacteraemia and antibiotic resistance of its pathogens reported in England and Wales between 1990 and 1998: trend analysis. Bmj 320 7229 (2000) 213-216
6. Tally F.P., and DeBruin M.F. Development of daptomycin for gram-positive infections. J Antimicrob Chemother 46 4 (2000) 523-526
7. Fuchs P.C., Barry A.L., and Brown S.D. In vitro bactericidal activity of daptomycin against staphylococci. J Antimicrob Chemother 49 3 (2002) 467-470
8. Silverman J.A., Perlmutter N.G., and Shapiro H.M. Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus. Antimicrob Agents Chemother 47 8 (2003) 2538-2544
9. Canepari P., Boaretti M., Lleo M.M., and Satta G. Lipoteichoic acid as a new target for activity of antibiotics: mode of action of daptomycin (LY146032). Antimicrob Agents Chemother 34 6 (1990) 1220-1226
10. Safdar N., Andes D., and Craig W.A. In vivo pharmacodynamic activity of daptomycin. Antimicrob Agents Chemother 48 1 (2004) 63-68
11. Wise R., Gee T., Andrews J.M., Dvorchik B., and Marshall G. Pharmacokinetics and inflammatory fluid penetration of intravenous daptomycin in volunteers. Antimicrob Agents Chemother 46 1 (2002) 31-33
12. Michiels M.J., and Bergeron M.G. Differential increased survival of staphylococci and limited ultrastructural changes in the core of infected fibrin clots after daptomycin administration. Antimicrob Agents Chemother 40 1 (1996) 203-211
13. Fluit A.C., Schmitz F.J., Verhoef J., and Milatovic D. Daptomycin in vitro susceptibility in European Gram-positive clinical isolates. Int J Antimicrob Agents 24 1 (2004) 59-66
14. Barry A.L., Fuchs P.C., and Brown S.D. In vitro activities of daptomycin against 2,789 clinical isolates from 11 North American medical centers. Antimicrob Agents Chemother 45 6 (2001) 1919-1922
15. Fuchs P.C., Barry A.L., and Brown S.D. Daptomycin susceptibility tests: interpretive criteria, quality control, and effect of calcium on in vitro tests. Diagn Microbiol Infect Dis 38 1 (2000) 51-58
16. Rybak M.J., Hershberger E., Moldovan T., and Grucz R.G. In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against Staphylococci and Enterococci, including vancomycin- intermediate and -resistant strains. Antimicrob Agents Chemother 44 4 (2000) 1062-1066
17. Snydman D.R., Jacobus N.V., McDermott L.A., Lonks J.R., and Boyce J.M. Comparative In vitro activities of daptomycin and vancomycin against resistant gram-positive pathogens. Antimicrob Agents Chemother 44 12 (2000) 3447-3450
18. Wise R., Andrews J.M., and Ashby J.P. Activity of daptomycin against Gram-positive pathogens: a comparison with other agents and the determination of a tentative breakpoint. J Antimicrob Chemother 48 4 (2001) 563-567
19. King A., and Phillips I. The in vitro activity of daptomycin against 514 Gram-positive aerobic clinical isolates. J Antimicrob Chemother 48 2 (2001) 219-223
20. Petersen P.J., Bradford P.A., Weiss W.J., Murphy T.M., Sum P.E., and Projan S.J. In vitro and in vivo activities of tigecycline (GAR-936), daptomycin, and comparative antimicrobial agents against glycopeptide-intermediate Staphylococcus aureus and other resistant gram-positive pathogens. Antimicrob Agents Chemother 46 8 (2002) 2595-2601
21. Critchley I.A., Blosser-Middleton R.S., Jones M.E., Thornsberry C., Sahm D.F., and Karlowsky J.A. Baseline study to determine in vitro activities of daptomycin against gram-positive pathogens isolated in the United States in 2000-2001. Antimicrob Agents Chemother 47 5 (2003) 1689-1693
22. Critchley I.A., Draghi D.C., Sahm D.F., Thornsberry C., Jones M.E., and Karlowsky J.A. Activity of daptomycin against susceptible and multidrug-resistant Gram-positive pathogens collected in the SECURE study (Europe) during 2000-2001. J Antimicrob Chemother 51 3 (2003) 639-649
23. Richter S.S., Kealey D.E., Murray C.T., Heilmann K.P., Coffman S.L., and Doern G.V. The in vitro activity of daptomycin against Staphylococcus aureus and Enterococcus species. J Antimicrob Chemother 52 1 (2003) 123-127
24. Streit J.M., Jones R.N., and Sader H.S. Daptomycin activity and spectrum: a worldwide sample of 6737 clinical Gram-positive organisms. J Antimicrob Chemother 53 4 (2004) 669-674
25. Arslan H., Azap O.K., Ergin F., Karaman S.O., and Oruc E. In vitro activity of daptomycin against isolates of Staphylococcus aureus and enterococci: first results from Turkey. Int J Antimicrob Agents 23 6 (2004) 642-643
26. Goldstein E.J., Citron D.M., Warren Y.A., Tyrrell K.L., Merriam C.V., and Fernandez H.T. In vitro activities of dalbavancin and 12 other agents against 329 aerobic and anaerobic gram-positive isolates recovered from diabetic foot infections. Antimicrob Agents Chemother 50 8 (2006) 2875-2879
27. Cilli F., Aydemir S., and Tunger A. In vitro activity of daptomycin alone and in combination with various antimicrobials against Gram-positive cocci. J Chemother 18 1 (2006) 27-32
28. Denis O., Deplano A., Nonhoff C., Hallin M., De Ryck R., Vanhoof R., et al. In vitro activities of ceftobiprole, tigecycline, daptomycin, and 19 other antimicrobials against methicillin-resistant Staphylococcus aureus strains from a national survey of Belgian hospitals. Antimicrob Agents Chemother 50 8 (2006) 2680-2685
29. LaPlante K.L., and Rybak M.J. Clinical glycopeptide-intermediate staphylococci tested against arbekacin, daptomycin, and tigecycline. Diagn Microbiol Infect Dis 50 2 (2004) 125-130
30. Diederen B.M., van Duijn I., Willemse P., and Kluytmans J.A. In vitro activity of daptomycin against methicillin-resistant Staphylococcus aureus, including heterogeneously glycopeptide-resistant strains. Antimicrob Agents Chemother 50 9 (2006) 3189-3191
31. Sader H.S., Streit J.M., Fritsche T.R., and Jones R.N. Antimicrobial activity of daptomycin against multidrug-resistant Gram-positive strains collected worldwide. Diagn Microbiol Infect Dis 50 3 (2004) 201-204
32. Goldstein E.J., Citron D.M., Merriam C.V., Warren Y., Tyrrell K., and Fernandez H.T. In vitro activities of dalbavancin and nine comparator agents against anaerobic gram-positive species and corynebacteria. Antimicrob Agents Chemother 47 6 (2003) 1968-1971
33. Goldstein E.J., Citron D.M., Merriam C.V., Warren Y.A., Tyrrell K.L., and Fernandez H.T. In vitro activities of daptomycin, vancomycin, quinupristin- dalfopristin, linezolid, and five other antimicrobials against 307 gram-positive anaerobic and 31 Corynebacterium clinical isolates. Antimicrob Agents Chemother 47 1 (2003) 337-341
34. Goldstein E.J., Citron D.M., Merriam C.V., Warren Y.A., Tyrrell K.L., and Fernandez H.T. In vitro activities of the new semisynthetic glycopeptide telavancin (TD-6424), vancomycin, daptomycin, linezolid, and four comparator agents against anaerobic gram-positive species and Corynebacterium spp. Antimicrob Agents Chemother 48 6 (2004) 2149-2152
35. Tyrrell K.L., Citron D.M., Warren Y.A., Fernandez H.T., Merriam C.V., and Goldstein E.J. In vitro activities of daptomycin, vancomycin, and penicillin against Clostridium difficile, C. perfringens, Finegoldia magna, and Propionibacterium acnes. Antimicrob Agents Chemother 50 8 (2006) 2728-2731
36. Huang Y.T., Liao C.H., Teng L.J., and Hsueh P.R. Daptomycin susceptibility of unusual gram-positive bacteria: comparison of the Etest and Broth Microdilution Method. Antimicrob Agents Chemother 51 4 (2007 Apr) 1570-1572
37. Johnson A.P., Mushtaq S., Warner M., and Livermore D.M. Calcium-supplemented daptomycin Etest strips for susceptibility testing on Iso-Sensitest agar. J Antimicrob Chemother 53 5 (2004) 860-862
38. Hayden M.K., Rezai K., Hayes R.A., Lolans K., Quinn J.P., and Weinstein R.A. Development of Daptomycin resistance in vivo in methicillin-resistant Staphylococcus aureus. J Clin Microbiol 43 10 (2005) 5285-5287
39. Jevitt L.A., Thorne G.M., Traczewski M.M., Jones R.N., McGowan Jr. J.E., Tenover F.C., et al. Multicenter evaluation of the Etest and disk diffusion methods for differentiating daptomycin-susceptible from non-daptomycin-susceptible Staphylococcus aureus isolates. J Clin Microbiol 44 9 (2006) 3098-3104
40. Sader H.S., Fritsche T.R., and Jones R.N. Daptomycin bactericidal activity and correlation between disk and broth microdilution method results in testing of Staphylococcus aureus strains with decreased susceptibility to vancomycin. Antimicrob Agents Chemother 50 7 (2006) 2330-2336
41. Fuchs P.C., Barry A.L., and Brown S.D. Evaluation of daptomycin susceptibility testing by Etest and the effect of different batches of media. J Antimicrob Chemother 48 4 (2001) 557-561
42. Jorgensen J.H., and Crawford S.A. Assessment of two commercial susceptibility test methods for determination of daptomycin MICs. J Clin Microbiol 44 6 (2006) 2126-2129
43. Koeth L.M., Leclercq R., and Olsson-Liljequist B. Comparison of daptomycin MIC results by DIN, NCCLS, SFM, and SRGA methods for 297 Gram-positive organisms. Int J Antimicrob Agents 23 1 (2004) 17-24
44. Arbeit R.D., Maki D., Tally F.P., Campanaro E., and Eisenstein B.I. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis 38 12 (2004) 1673-1681
45. Lipsky B.A., and Stoutenburgh U. Daptomycin for treating infected diabetic foot ulcers: evidence from a randomized, controlled trial comparing daptomycin with vancomycin or semi-synthetic penicillins for complicated skin and skin-structure infections. J Antimicrob Chemother 55 2 (2005) 240-245
46. Martone W.J., and Lamp K.C. Efficacy of daptomycin in complicated skin and skin-structure infections due to methicillin-sensitive and -resistant Staphylococcus aureus: results from the CORE Registry. Curr Med Res Opin 22 12 (2006) 2337-2343
47. Fowler Jr. V.G., Boucher H.W., Corey G.R., Abrutyn E., Karchmer A.W., Rupp M.E., et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 355 7 (2006) 653-665
48. Korzeniowski O., and Sande M.A. Combination antimicrobial therapy for Staphylococcus aureus endocarditis in patients addicted to parenteral drugs and in nonaddicts: a prospective study. Ann Intern Med 97 4 (1982) 496-503
49. Poutsiaka D.D., Skiffington S., Miller K.B., Hadley S., and Snydman D.R. Daptomycin in the treatment of vancomycin-resistant Enterococcus faecium bacteremia in neutropenic patients. J Infect 54 6 (2007 Jun) 567-571
50. Segreti J.A., Crank C.W., and Finney M.S. Daptomycin for the treatment of gram-positive bacteremia and infective endocarditis: a retrospective case series of 31 patients. Pharmacotherapy 26 3 (2006) 347-352
51. Mohan S.S., McDermott B.P., and Cunha B.A. Methicillin-resistant Staphylococcus aureus prosthetic aortic valve endocarditis with paravalvular abscess treated with daptomycin. Heart Lung 34 1 (2005) 69-71
52. Cunha B.A., Eisenstein L.E., and Hamid N.S. Pacemaker-induced Staphylococcus aureus mitral valve acute bacterial endocarditis complicated by persistent bacteremia from a coronary stent: cure with prolonged/high-dose daptomycin without toxicity. Heart Lung 35 3 (2006) 207-211
53. Shah M., and Murillo J.L. Successful treatment of Corynebacterium striatum endocarditis with daptomycin plus rifampin. Ann Pharmacother 39 10 (2005) 1741-1744
54. Rouse M.S., Piper K.E., Jacobson M., Jacofsky D.J., Steckelberg J.M., and Patel R. Daptomycin treatment of Staphylococcus aureus experimental chronic osteomyelitis. J Antimicrob Chemother 57 2 (2006) 301-305
55. Finney M.S., Crank C.W., and Segreti J. Use of daptomycin to treat drug-resistant Gram-positive bone and joint infections. Curr Med Res Opin 21 12 (2005) 1923-1926
56. Silverman J.A., Mortin L.I., Vanpraagh A.D., Li T., and Alder J. Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact. J Infect Dis 191 12 (2005) 2149-2152
57. Karas J.A., Enoch D.A., and Emery M.M. Community-onset healthcare-associated MRSA bacteraemia in a district general hospital. J Hosp Infect 62 4 (2006) 480-486
58. Wagenlehner F.M., Lehn N., Witte W., and Naber K.G. In vitro activity of daptomycin versus linezolid and vancomycin against gram-positive uropathogens and ampicillin against enterococci, causing complicated urinary tract infections. Chemotherapy 51 2-3 (2005) 64-69
59. Rand K.H., and Houck H. Daptomycin synergy with rifampicin and ampicillin against vancomycin-resistant enterococci. J Antimicrob Chemother 53 3 (2004) 530-532
60. Pankey G., Ashcraft D., and Patel N. In vitro synergy of daptomycin plus rifampin against Enterococcus faecium resistant to both linezolid and vancomycin. Antimicrob Agents Chemother 49 12 (2005) 5166-5168
61. Rand K.H., and Houck H.J. Synergy of daptomycin with oxacillin and other beta-lactams against methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 48 8 (2004) 2871-2875
62. Tsuji B.T., and Rybak M.J. Short-course gentamicin in combination with daptomycin or vancomycin against Staphylococcus aureus in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob Agents Chemother 49 7 (2005) 2735-2745
63. Credito K., Lin G., and Appelbaum P.C. Activity of Daptomycin alone and in combination with rifampin and gentamicin against Staphylococcus aureus by time-kill methodology. Antimicrob Agents Chemother 51 (2007) 1504-1507
64. Scheetz M., Reddy P., Postelnick M., and Flaherty J. In vivo synergy of daptomycin plus a penicillin agent for MRSA?. J Antimicrob Chemother 55 3 (2005) 398-399
65. Burns C.A. Daptomycin-rifampin for a recurrent MRSA joint infection unresponsive to vancomycin-based therapy. Scand J Infect Dis 38 2 (2006) 133-136
66. Antony S.J. Combination therapy with daptomycin, vancomycin, and rifampin for recurrent, severe bone and prosthetic joint infections involving methicillin-resistant Staphylococcus aureus. Scand J Infect Dis 38 4 (2006) 293-295
67. Skiest D.J. Treatment failure resulting from resistance of Staphylococcus aureus to daptomycin. J Clin Microbiol 44 2 (2006) 655-656
68. Marty F.M., Yeh W.W., Wennersten C.B., Venkataraman L., Albano E., Alyea E.P., et al. Emergence of a clinical daptomycin-resistant Staphylococcus aureus isolate during treatment of methicillin-resistant Staphylococcus aureus bacteremia and osteomyelitis. J Clin Microbiol 44 2 (2006) 595-597
69. Mariani P.G., Sader H.S., and Jones R.N. Development of decreased susceptibility to daptomycin and vancomycin in a Staphylococcus aureus strain during prolonged therapy. J Antimicrob Chemother 58 2 (2006) 481-483
70. Mangili A., Bica I., Snydman D.R., and Hamer D.H. Daptomycin-resistant, methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 40 7 (2005) 1058-1060
71. Vikram H.R., Havill N.L., Koeth L.M., and Boyce J.M. Clinical progression of methicillin-resistant Staphylococcus aureus vertebral osteomyelitis associated with reduced susceptibility to daptomycin. J Clin Microbiol 43 10 (2005) 5384-5387
72. Hirschwerk D., Ginocchio C.C., Bythrow M., and Condon S. Diminished susceptibility to daptomycin accompanied by clinical failure in a patient with methicillin-resistant Staphylococcus aureus bacteremia. Infect Control Hosp Epidemiol 27 3 (2006) 315-317
73. Long J.K., Choueiri T.K., Hall G.S., Avery R.K., and Sekeres M.A. Daptomycin-resistant Enterococcus faecium in a patient with acute myeloid leukemia. Mayo Clin Proc 80 9 (2005) 1215-1216
74. Lewis II J.S., Owens A., Cadena J., Sabol K., Patterson J.E., and Jorgensen J.H. Emergence of daptomycin resistance in Enterococcus faecium during daptomycin therapy. Antimicrob Agents Chemother 49 4 (2005) 1664-1665
75. Munoz-Price L.S., Lolans K., and Quinn J.P. Emergence of resistance to daptomycin during treatment of vancomycin-resistant Enterococcus faecalis infection. Clin Infect Dis 41 4 (2005) 565-566
76. Green M.R., Anasetti C., Sandin R.L., Rolfe N.E., and Greene J.N. Development of daptomycin resistance in a bone marrow transplant patient with vancomycin-resistant Enterococcus durans. J Oncol Pharm Pract 12 3 (2006) 179-181
77. Lesho E.P., Wortmann G.W., Craft D., and Moran K.A. De novo daptomycin nonsusceptibility in a clinical isolate. J Clin Microbiol 44 2 (2006) 673
78. Silverman J.A., Oliver N., Andrew T., and Li T. Resistance studies with daptomycin. Antimicrob Agents Chemother 45 6 (2001) 1799-1802
79. Friedman L., Alder J.D., and Silverman J.A. Genetic changes that correlate with reduced susceptibility to daptomycin in Staphylococcus aureus. Antimicrob Agents Chemother 50 6 (2006) 2137-2145
80. Cui L., Tominaga E., Neoh H.M., and Hiramatsu K. Correlation between reduced Daptomycin susceptibility and Vancomycin resistance in Vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother 50 3 (2006) 1079-1082
81. Sakoulas G., Alder J., Thauvin-Eliopoulos C., Moellering Jr. R.C., and Eliopoulos G.M. Induction of daptomycin heterogeneous susceptibility in Staphylococcus aureus by exposure to vancomycin. Antimicrob Agents Chemother 50 4 (2006) 1581-1585
82. Hiramatsu K. Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistance. Lancet Infect Dis 1 3 (2001) 147-155
83. Echevarria K., Datta P., Cadena J., and Lewis II J.S. Severe myopathy and possible hepatotoxicity related to daptomycin. J Antimicrob Chemother 55 4 (2005) 599-600
84. Papadopoulos S., Ball A.M., Liewer S.E., Martin C.A., Winstead P.S., and Murphy B.S. Rhabdomyolysis during therapy with daptomycin. Clin Infect Dis 42 12 (2006) e108-e110
85. Hayes Jr. D., Anstead M.I., and Kuhn R.J. Eosinophilic pneumonia induced by daptomycin. J Infect 54 4 (2007 Apr) e211-e213
86. Carpenter C.F., and Chambers H.F. Daptomycin: another novel agent for treating infections due to drug-resistant gram-positive pathogens. Clin Infect Dis 38 7 (2004) 994-1000